{
    "clinical_study": {
        "@rank": "53502", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra Single Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, single-arm extension study will evaluate the long-term safety\n      of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.  Patients who have\n      completed the MA21488 core study and the ML21530 study and who could benefit from the study\n      drug, according to the opinion of the investigator, will receive 8 mg/kg of intravenous\n      RoActemra/Actemra every four weeks. The anticipated time on study treatment is 104 weeks."
        }, 
        "brief_title": "A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients that have completed their last visit ML21530 and MA21488 in core studies and\n             that might benefit from treatment using the study drug according to the\n             investigator's evaluation\n\n          -  Absence of an adverse event (AE) or current or recent laboratory finding that would\n             prevent the use of the 8 mg/kg dose of the RoActemra/Actemra study drug\n\n          -  Receiving outpatient treatment\n\n          -  For women who are not postmenopausal and are not surgically sterile: agreement to use\n             at least one adequate method of contraception\n\n        Exclusion Criteria:\n\n          -  Patients who have prematurely discontinued ML21530 and MA21488 core studies for any\n             reason\n\n          -  MA21488 study patients who remained untreated with tocilizumab after it's\n             discontinuation according to the treatment-free remission criteria from MA21488\n             study.\n\n          -  Immunization with a live/attenuated vaccine since the last administration of the\n             study drug in ML21530 and MA 21488 core studies\n\n          -  Diagnosis after the last visit in ML21530 study or after the last visit in MA21488\n             study of a rheumatic autoimmune disease and/or an inflammatory joint disease other\n             than rheumatoid arthritis\n\n          -  Abnormal laboratory parameters at the baseline\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine\n             monoclonal antibodies\n\n          -  Evidences of a concomitant, serious and uncontrolled illness\n\n          -  Known active condition or a history of recurrent infections by bacteria, viruses,\n             fungi, mycobacteria or other agents\n\n          -  Evidence of an active malignant disease, malignancies diagnosed in the last 10 years\n             or breast cancer diagnosed in the last 20 years\n\n          -  History of drugs of abuse since the inclusion in the ML21530 and MA21488 core studies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715831", 
            "org_study_id": "ML28091"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra Single Arm", 
            "description": "8 mg/kg intravenously every 4 weeks for 104 weeks", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Salvador", 
                        "country": "Brazil", 
                        "state": "BA", 
                        "zip": "40050-410"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitoria", 
                        "country": "Brazil", 
                        "state": "ES", 
                        "zip": "29043-910"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Juiz de Fora", 
                        "country": "Brazil", 
                        "state": "MG", 
                        "zip": "36010-570"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "20551-030"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "RS", 
                        "zip": "90610-000"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Campinas", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "13077-005"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Jose do Rio Preto", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "15090-000"
                    }
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04039-004"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04026-000"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04027-000"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil", 
                        "state": "SP", 
                        "zip": "04266-010"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-Label, Single-Arm Extension Study To Describe The Safety Of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 And MA21488 And Presenting An Indication Of Maintaining The Tocilizumab Treatment", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28091 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Long-term Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Disease Activity Index 28-Erythocyte Sedimentation Rate (DAS28-ESR)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to approximately 2 years"
            }, 
            {
                "measure": "Change in tender joint count (TJC)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to approximately 2 years"
            }, 
            {
                "measure": "Change in swollen joint count (SJC)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to approximately 2 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}